Pubfacts - Scientific Publication Data
  • Categories
  • Journals
  • ->
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:
Get 20% Off Journals at LWW.com

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.

Authors:
Emanuele Andreano Giulia Piccini Danilo Licastro Lorenzo Casalino Nicole V Johnson Ida Paciello Simeone Dal Monego Elisa Pantano Noemi Manganaro Alessandro Manenti Rachele Manna Elisa Casa Inesa Hyseni Linda Benincasa Emanuele Montomoli Rommie E Amaro Jason S McLellan Rino Rappuoli

bioRxiv 2020 Dec 28. Epub 2020 Dec 28.

To investigate the evolution of SARS-CoV-2 in the immune population, we co-incubated authentic virus with a highly neutralizing plasma from a COVID-19 convalescent patient. The plasma fully neutralized the virus for 7 passages, but after 45 days, the deletion of F140 in the spike N-terminal domain (NTD) N3 loop led to partial breakthrough. At day 73, an E484K substitution in the receptor-binding domain (RBD) occurred, followed at day 80 by an insertion in the NTD N5 loop containing a new glycan sequon, which generated a variant completely resistant to plasma neutralization. Computational modeling predicts that the deletion and insertion in loops N3 and N5 prevent binding of neutralizing antibodies. The recent emergence in the United Kingdom and South Africa of natural variants with similar changes suggests that SARS-CoV-2 has the potential to escape an effective immune response and that vaccines and antibodies able to control emerging variants should be developed.

One Sentence Summary: Three mutations allowed SARS-CoV-2 to evade the polyclonal antibody response of a highly neutralizing COVID-19 convalescent plasma.

Download full-text PDF

Source
http://dx.doi.org/10.1101/2020.12.28.424451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781313PMC
December 2020

Publication Analysis

Top Keywords

highly neutralizing
12
covid-19 convalescent
12
ntd loop
8
convalescent plasma
8
neutralizing covid-19
8
plasma
5
glycan sequon
4
sars-cov-2
4
control emerging
4
loop glycan
4
emerging variants
4
sequon generated
4
generated variant
4
antibodies control
4
vaccines antibodies
4
insertion ntd
4
resistant plasma
4
completely resistant
4
variant completely
4
domain rbd
4

Altmetric Statistics


Show full details
3791 Total Shares
2 Facebook Pages
2 Blogs
30 News Outlets
3126 Tweets
3160 Citations

Similar Publications

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins.

Authors:
Harald Hefter Christian J Hartmann Ulrike Kahlen Sara Samadzadeh Dietmar Rosenthal Marek Moll

Front Neurol 2021 9;12:636590. Epub 2021 Feb 9.

Department of Neurology, University of Düsseldorf, Düsseldorf, Germany.

This study investigated the clinical long-term effect of incobotulinumtoxinA (incoBoNT/A) in 33 cervical dystonia (CD) patients who had developed partial secondary therapy failure (PSTF) under previous long-term botulinum toxin (BoNT) treatment. Patients were treated four times every 12 weeks with incoBoNT/A injections. Physicians assessed treatment efficacy using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) at the baseline visit, week 12 and 48. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.

Authors:
Amnon A Berger Ariel Winnick Daniel Popovsky Alicia Kaneb Kevin Berardino Adam M Kaye Elyse M Cornett Alan D Kaye Omar Viswanath Ivan Urits

Psychopharmacol Bull 2020 Oct;50(4 Suppl 1):163-188

Berger, MD, PhD, Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA. Winnick, MA, Soroka University Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; School of Optometry, University of California, Berkeley, Berkeley, CA. Popovsky, MS, Kaneb, BA, Berardino, BS, Georgetown University School of Medicine, Washington DC. Kaye, Pharm D, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Department of Pharmacy Practice, Stockton, CA. Cornett, PhD, Department of Anesthesiology, Louisiana State University School of Medicine, Shreveport, LA. Kaye, MD, PhD, Departments of Anesthesiology and Pharmacology, Toxicology and Neurosciences, Louisiana State University School of Medicine, Shreveport, LA. Viswanath, MD, Department of Anesthesiology, Louisiana State University School of Medicine, Shreveport, LA; Valley Pain Consultants - Envision Physician Services, Phoenix, AZ; University of Arizona College of Medicine-Phoenix, Department of Anesthesiology, Phoenix, AZ; Creighton University School of Medicine, Department of Anesthesiology, Omaha, NE. Urits, MD, Department of Anesthesiology, Louisiana State University School of Medicine, Shreveport, LA; Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care and Pain Medicine, Harvard Medical School, Boston, MA.

Migraines are a common form of primary headache, affecting women more than men (17.4% and 5.7% of US population, respectively, a total of 12%) that carry significant morbidity and disability, as well as a hefty healthcare price tag. Read More

View Article and Full-Text PDF
October 2020
Similar Publications

Generation and immunogenicity analysis of recombinant classical swine fever virus glycoprotein E2 and E expressed in baculovirus expression system.

Authors:
Qiang Wei Yilin Bai Yapeng Song Yunchao Liu Wei Yu Yaning Sun Li Wang Ruiguang Deng Guangxu Xing Gaiping Zhang

Virol J 2021 Feb 24;18(1):44. Epub 2021 Feb 24.

Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou, 450002, China.

Classical swine fever (CSF) caused by the classical swine fever virus (CSFV) is a highly contagious swine disease resulting in large economical losses worldwide. The viral envelope glycoprotein E2 and E are major targets for eliciting antibodies against CSFV in infected animals. In this report, the glycoprotein E2 and E were expressed using the baculovirus system and their protective immunity in rabbits were tested. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.

Authors:
Emma C Thomson Laura E Rosen James G Shepherd Roberto Spreafico Ana da Silva Filipe Jason A Wojcechowskyj Chris Davis Luca Piccoli David J Pascall Josh Dillen Spyros Lytras Nadine Czudnochowski Rajiv Shah Marcel Meury Natasha Jesudason Anna De Marco Kathy Li Jessica Bassi Aine O'Toole Dora Pinto Rachel M Colquhoun Katja Culap Ben Jackson Fabrizia Zatta Andrew Rambaut Stefano Jaconi Vattipally B Sreenu Jay Nix Ivy Zhang Ruth F Jarrett William G Glass Martina Beltramello Kyriaki Nomikou Matteo Pizzuto Lily Tong Elisabetta Cameroni Tristan I Croll Natasha Johnson Julia Di Iulio Arthur Wickenhagen Alessandro Ceschi Aoife M Harbison Daniel Mair Paolo Ferrari Katherine Smollett Federica Sallusto Stephen Carmichael Christian Garzoni Jenna Nichols Massimo Galli Joseph Hughes Agostino Riva Antonia Ho Marco Schiuma Malcolm G Semple Peter J M Openshaw Elisa Fadda J Kenneth Baillie John D Chodera Suzannah J Rihn Samantha J Lycett Herbert W Virgin Amalio Telenti Davide Corti David L Robertson Gyorgy Snell

Cell 2021 Jan 28. Epub 2021 Jan 28.

Vir Biotechnology, San Francisco, CA 94158, USA. Electronic address:

SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. Read More

View Article and Full-Text PDF
January 2021
Similar Publications

Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

Authors:
Wilfredo F Garcia-Beltran Evan C Lam Kerri St Denis Adam D Nitido Zeidy H Garcia Blake M Hauser Jared Feldman Maia N Pavlovic David J Gregory Mark C Poznansky Alex Sigal Aaron G Schmidt A John Iafrate Vivek Naranbhai Alejandro B Balazs

medRxiv 2021 Feb 18. Epub 2021 Feb 18.

Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of globally circulating variants, we evaluated the neutralization potency of 48 sera from BNT162b2 and mRNA-1273 vaccine recipients against pseudoviruses bearing spike proteins derived from 10 strains of SARS-CoV-2. Read More

View Article and Full-Text PDF
February 2021
Similar Publications
Save 15% Survey
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap